株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌治療向けジェネリック医薬品市場の分析

Cancer Generics Market Outlook 2017

発行 RNCOS E-Services Pvt. Ltd. 商品コード 212646
出版日 ページ情報 英文 95 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。
Back to Top
癌治療向けジェネリック医薬品市場の分析 Cancer Generics Market Outlook 2017
出版日: 2013年07月01日 ページ情報: 英文 95 Pages
概要

世界における癌治療向けジェネリック医薬品(ジェネリック抗癌剤)市場は、2017年には190億米ドルの規模に達すると予測されています。

当レポートでは、世界のジェネリック抗癌剤市場について調査分析し、市場の現状と見通し、促進要因と動向、セグメント別の医薬品動向などを検証し、主要企業プロファイルも含めて、概略以下の構成でお届けいたします。

第1章 アナリストの見解

第2章 調査手法

第3章 癌の発症率:現在/将来予測

第4章 癌治療市場の見通し:現在/将来

  • ジェネリック抗癌剤:市場規模

第5章 市場の促進要因と動向

  • インドのジェネリック医薬品が米国での販売承認を取得
  • 癌の罹患率の増加が、ジェネリック医薬品市場をけん引
  • 戦略的活動・提携の増加
  • 特許期限切れがジェネリック医薬品市場の後押しを継続
  • 企業:新しいジェネリック抗癌剤を求める

第6章 ジェネリック抗癌剤:疾病の種類別

  • 肺癌
  • 乳癌
  • 大腸癌
  • 胃癌
  • 前立腺癌

第7章 ジェネリック抗癌剤:経口/注入別

  • 経口ジェネリック医薬品
    • Arimidex (Anastrozole)
    • Casodex (Bicalutamide)
    • Aromasin (Exemestane)
    • Femara (Letrozole)
    • Megace (Megestrol Acetate)
    • Purinethol (Mercaptopurine)
    • Tarceva (Erlotinib)
    • Nolvadex (Tamoxifen Citrate)
    • Eulexin (Flutamide)
    • Hydrea (Hydroxyurea)
  • 注入ジェネリック医薬品
    • Camptosar (Irinotecan Hydrochloride)
    • Velcade (Bortezomib)
    • Taxotere (Docetaxel)
    • Gemzar (Gemcitabine Hydrochloride)
    • Doxil (Liposomal)
    • Ifex (Ifosfamide)

第8章 主要企業

  • Actavis Inc.
  • Mylan
  • Roxane Laboratories
  • Accord Healthcare
  • Sun Pharmaceuticals
  • Teva
  • Fresnius Kabi

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The National Cancer Institute has stated that almost half of the population born today will be diagnosed with cancer at some point during their lifetime. With global cancer incidence rising to almost 13 Million in 2012 and majority of blockbuster cancer drugs losing their patent protection, the market for cancer generics is bound to experience prodigious growth.

According to our latest research report “Cancer Generics Market Outlook 2017”, this market for cancer generics is expected to grow at 13%, reaching US$ 19 Billion by 2017. The low pricing of cancer generics and increased life expectancy will be the major contributors in this growth.

The report provides an insight to the various parameters associated with Cancer Generics. It focuses on the trends and drivers instrumental in shaping the market, evaluating the role of each driver in detail and predicting its possible impact. Also covered is the segmentation of the generics market by disease types, with emphasis on current and future incidence, regional analysis and the patent expiration status of key cancer drugs.

After an exhaustive study, we have segmented the generics market by the various oral and injectable options, encompassing all the recently approved generics along with existing ones. The detailed study of each drug comprises of price analysis of the branded and generic drug, miscellaneous manufacturers of each generic drug, and drug applicability. Also included are the recent developments of generic players in terms of FDA clearances, mergers and acquisitions that have helped them emerge as the key manufacturers.

The thorough study asserts that Cancer Generics is going to be the focus area for majority of players, with the market witnessing entry of a whole range of generics thereby labeling Cancer Generics as a field with enormous growth potential in the near future.

Table of Contents

1. Analyst View

2. Research Methodology

3. Cancer Incidences - Current and Future Projection

4. Cancer Market Outlook: Current and Future

  • 4.1. Cancer Generics: Market Size

5. Market Drivers and Trends

  • 5.1. Indian Generics Getting Marketing Approval in US
  • 5.2. Increasing Cancer Prevalence: Driving Generics Market
  • 5.3. Strategic Activity and Alliances on the Rise
  • 5.4. Patent Expiration Continue to Boost Generics Market
  • 5.5. Companies Thriving for New Cancer Generics

6. Cancer Generics: Market Segmentation by Disease Type

  • 6.1. Lung Cancer
    • 6.1.1. Current and Future Incidence
    • 6.1.2. Regional Analysis
    • 6.1.3. Commercialized Drugs: Branded and Generics
  • 6.2. Breast Cancer
    • 6.2.1. Current and Future Incidence
    • 6.2.2. Regional Analysis
    • 6.2.3. Commercialized Drugs: Branded and Generics
  • 6.3. Colorectal Cancer
    • 6.3.1. Current and Future Incidence
    • 6.3.2. Regional Analysis
    • 6.3.3. Commercialized Drugs: Branded and Generics
  • 6.4. Stomach Cancer
    • 6.4.1. Current and Future Incidence
    • 6.4.2. Regional Analysis
    • 6.4.3. Commercialized Drugs: Branded and Generics
  • 6.5. Prostate Cancer
    • 6.5.1. Current and Future Incidence
    • 6.5.2. Regional Analysis
    • 6.5.3. Commercialized Drugs: Branded and Generics

7. Cancer Generic Drugs: Market Segmentation by Oral and Injectables

  • 7.1. Oral Generic Drugs
    • 7.1.1. Arimidex (Anastrozole)
    • 7.1.2. Casodex (Bicalutamide)
    • 7.1.3. Aromasin (Exemestane)
    • 7.1.4. Femara (Letrozole)
    • 7.1.5. Megace (Megestrol Acetate)
    • 7.1.6. Purinethol (Mercaptopurine)
    • 7.1.7. Tarceva (Erlotinib)
    • 7.1.8. Nolvadex (Tamoxifen Citrate)
    • 7.1.9. Eulexin (Flutamide)
    • 7.1.10. Hydrea (Hydroxyurea)
  • 7.2. Generic Injectables
    • 7.2.1. Camptosar (Irinotecan Hydrochloride)
    • 7.2.2. Velcade (Bortezomib)
    • 7.2.3. Taxotere (Docetaxel)
    • 7.2.4. Gemzar (Gemcitabine Hydrochloride)
    • 7.2.5. Doxil (Liposomal)
    • 7.2.6. Ifex (Ifosfamide)

8. Key Players

  • 8.1. Actavis Inc.
  • 8.2. Mylan
  • 8.3. Roxane Laboratories
  • 8.4. Accord Healthcare
  • 8.5. Sun Pharmaceuticals
  • 8.6. Teva
  • 8.7. Fresnius Kabi

List of Figures:

  • Figure 3-1: Global - Number of New Cancer Cases (Million), 2012 & 2020
  • Figure 4-1: Global - Cancer Drugs Market (Billion US$), 2012-2017
  • Figure 4-2: Global - Cancer Drugs Market by Drug Class (%), 2013
  • Figure 4-3: Global - Cancer Generics Market (Billion US$), 2012-2017
  • Figure 6-1: Global - Number of New Lung Cancer Cases (Million), 2009 & 2020
  • Figure 6-2: Global - New Lung Cancer Cases by Region (%), 2009
  • Figure 6-3: Global - Forecast for New Lung Cancer Cases by Region (%), 2020
  • Figure 6-4: Global - Number of New Breast Cancer Cases (Million), 2009 & 2020
  • Figure 6-5: Global - New Breast Cancer Cases by Region (%), 2009
  • Figure 6-6: Global - Forecast for New Breast Cancer Cases by Region (%), 2020
  • Figure 6-7: Global - Number of New Colorectal Cancer Cases (Million), 2009 & 2020
  • Figure 6-8: Global - New Colorectal Cancer Cases by Region (%), 2009
  • Figure 6-9: Global - Forecast for New Colorectal Cancer Cases by Region (%), 2020
  • Figure 6-10: Global - Number of New Stomach Cancer Cases (Million), 2009 & 2020
  • Figure 6-11: Global - New Stomach Cancer Cases by Region (%), 2009
  • Figure 6-12: Global - Forecast for New Stomach Cancer Cases by Region (%), 2020
  • Figure 6-13: Global - Number of New Prostate Cancer Cases (Million), 2009 & 2020
  • Figure 6-14: Global - New Prostate Cancer Cases by Region (%), 2009
  • Figure 6-15: Global - Forecast for New Prostate Cancer Cases by Region (%), 2020

List of Tables:

  • Table 3-1: Global - New Cases of Top Five Cancer's by Geography (Number), 2009
  • Table 3-2: Global - Forecast for New Cases of Top Five Cancer's by Geography (Number), 2020
  • Table 5-1: Oncology Drug Master Filings by Market Players
  • Table 6-1: Global - Key Lung Cancer Drugs and Patent Expiry Status
  • Table 6-2: Global - Key Breast Cancer Drugs and Patent Expiry Status
  • Table 6-3: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
  • Table 6-4: Global - Key Stomach Cancer Drugs and Patent Expiry Status
  • Table 6-5: Global - Key Prostate Cancer Drugs and Patent Expiry Status
  • Table 7-1: List of Companies Dealing in Generic Arimidex (Anastrozole)
  • Table 7-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
  • Table 7-3: List of Companies Dealing in Generic Casodex (Bicalutamide)
  • Table 7-4: Cost Comparison of Generics and Branded Casodex (Bicalutamide)
  • Table 7-5: Cost Comparison of Generics and Branded Aromasin (Exemestane)
  • Table 7-6: List of Companies Dealing in Generic Femara (Letrozole)
  • Table 7-7: Cost Comparison of Generics and Branded Femara (Letrozole)
  • Table 7-8: List of Companies Dealing in Generic Megace (Megestrol Acetate)
  • Table 7-9: Cost Comparison of Generics and Branded Megace (Megestrol Acetate)
  • Table 7-10: List of Companies Dealing in Generic Purinethol (Mercaptopurine)
  • Table 7-11 Cost Comparison of Generics and Branded Purinethol (Mercaptopurine)
  • Table 7-12 Cost Comparison of Generics and Branded Tarceva (Erlotinib)
  • Table 7-13: List of Companies Dealing in Generic Nolvadex (Tamoxifen Citrate)
  • Table 7-14 Cost Comparison of Generics and Branded Nolvadex (Tamoxifen Citrate)
  • Table 7-15: List of Companies Dealing in Generic Eulexin (Flutamide)
  • Table 7-16 Cost Comparison of Generics and Branded Eulexin (Flutamide)
  • Table 7-17: List of Companies Dealing in Generic Hydrea (Hydroxyurea)
  • Table 7-18: Cost Comparison of Generics and Branded Hydrea (Hydroxyurea)
  • Table 7-19: List of Companies Dealing in Generic Camptosar (Irinotecan Hydrochloride)
  • Table 7-20: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
  • Table 7-21: Cost Comparison of Generics and Branded Velcade (bortezomib)
  • Table 7-22: List of Companies Dealing in Generic Taxotere (Docetaxel)
  • Table 7-23 Cost Comparison of Generics and Branded Taxotere (Docetaxel)
  • Table 7-24: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
  • Table 7-25: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
  • Table 7-26: Cost Comparison of Generics and Branded Doxil (Doxorubicin Hydrochloride)
  • Table 7-27: List of Companies Dealing in Generic Ifex (Ifosfamide)
  • Table 8-1: Actavis - Key Cancer Generic Drugs
  • Table 8-2: Mylan - Key Cancer Generic Drugs
  • Table 8-3: Roxane - Key Cancer Generic Drugs
  • Table 8-4: Accord Healthcare - Key Cancer Generic Drugs
  • Table 8-5: Sun Pharmaceuticals - Key Cancer Generic Drugs
  • Table 8-6: Teva Pharmaceuticals - Key Cancer Generic Drugs
  • Table 8-7: Fresnius Kabi Pharmaceuticals - Key Cancer Generic Drugs
Back to Top